Cargando…

Pediatric Behçet’s disease: Experience of a single tertiary center

OBJECTIVES: The aim of this study was to examine the clinical and phenotypic features of pediatric Behçet’s disease (PEDBD) in our clinic and present the rates of fulfilling the diagnostic criteria. PATIENTS AND METHODS: Thirty-four patients (20 males, 14 females; mean age: 16.0±2.1 years; range, 10...

Descripción completa

Detalles Bibliográficos
Autores principales: Açarı, Ceyhun, İşgüder, Rana, Torun, Rüya, Makay, Balahan, Ünsal, Şevket Erbil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Turkish League Against Rheumatism 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481698/
https://www.ncbi.nlm.nih.gov/pubmed/37680516
http://dx.doi.org/10.46497/ArchRheumatol.2023.9651
_version_ 1785102034185224192
author Açarı, Ceyhun
İşgüder, Rana
Torun, Rüya
Makay, Balahan
Ünsal, Şevket Erbil
author_facet Açarı, Ceyhun
İşgüder, Rana
Torun, Rüya
Makay, Balahan
Ünsal, Şevket Erbil
author_sort Açarı, Ceyhun
collection PubMed
description OBJECTIVES: The aim of this study was to examine the clinical and phenotypic features of pediatric Behçet’s disease (PEDBD) in our clinic and present the rates of fulfilling the diagnostic criteria. PATIENTS AND METHODS: Thirty-four patients (20 males, 14 females; mean age: 16.0±2.1 years; range, 10 to 18 years) diagnosed with PEDBD between January 2010 and December 2019 were retrospectively evaluated. Patients were reclassified according to 1990 International Study Group (ISG) criteria, 2014 International Criteria for Behçet’s Disease (ICBD), and PEDBD criteria. RESULTS: The mean age at diagnosis was 12.6±3.1 years, the median diagnosis delay time was 12.0 (range, 4.5 to 27.0) months, and the mean age at symptom onset was 10.8±2.9 years. The mean follow-up period was 31.9±20.9 months. Oral aphthous ulcer was observed in 33 (97.1%), genital ulcer in 16 (47.0%), ocular involvement in 15 (44.1%), skin lesion in 11 (32.3%), joint involvement in nine (26.4%), both vascular and neurological involvement in six (17.6%) patients. The pathergy test was positive in 11 (37.8%) patients, and human leukocyte antigen (HLA)-B51 was positive in 11 (78.5%) of 14 patients. The rates of patients meeting the criteria for ISG, ICBD, and PEDBD were 52.9%, 82.4%, and 50.0%, respectively. CONCLUSION: Pathergy and HLA-B51 can be used as supportive findings in patients who do not meet the diagnostic criteria. However, expert opinion is still the gold standard in diagnosis.
format Online
Article
Text
id pubmed-10481698
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Turkish League Against Rheumatism
record_format MEDLINE/PubMed
spelling pubmed-104816982023-09-07 Pediatric Behçet’s disease: Experience of a single tertiary center Açarı, Ceyhun İşgüder, Rana Torun, Rüya Makay, Balahan Ünsal, Şevket Erbil Arch Rheumatol Original Article OBJECTIVES: The aim of this study was to examine the clinical and phenotypic features of pediatric Behçet’s disease (PEDBD) in our clinic and present the rates of fulfilling the diagnostic criteria. PATIENTS AND METHODS: Thirty-four patients (20 males, 14 females; mean age: 16.0±2.1 years; range, 10 to 18 years) diagnosed with PEDBD between January 2010 and December 2019 were retrospectively evaluated. Patients were reclassified according to 1990 International Study Group (ISG) criteria, 2014 International Criteria for Behçet’s Disease (ICBD), and PEDBD criteria. RESULTS: The mean age at diagnosis was 12.6±3.1 years, the median diagnosis delay time was 12.0 (range, 4.5 to 27.0) months, and the mean age at symptom onset was 10.8±2.9 years. The mean follow-up period was 31.9±20.9 months. Oral aphthous ulcer was observed in 33 (97.1%), genital ulcer in 16 (47.0%), ocular involvement in 15 (44.1%), skin lesion in 11 (32.3%), joint involvement in nine (26.4%), both vascular and neurological involvement in six (17.6%) patients. The pathergy test was positive in 11 (37.8%) patients, and human leukocyte antigen (HLA)-B51 was positive in 11 (78.5%) of 14 patients. The rates of patients meeting the criteria for ISG, ICBD, and PEDBD were 52.9%, 82.4%, and 50.0%, respectively. CONCLUSION: Pathergy and HLA-B51 can be used as supportive findings in patients who do not meet the diagnostic criteria. However, expert opinion is still the gold standard in diagnosis. Turkish League Against Rheumatism 2022-10-21 /pmc/articles/PMC10481698/ /pubmed/37680516 http://dx.doi.org/10.46497/ArchRheumatol.2023.9651 Text en Copyright © 2023, Turkish League Against Rheumatism https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Article
Açarı, Ceyhun
İşgüder, Rana
Torun, Rüya
Makay, Balahan
Ünsal, Şevket Erbil
Pediatric Behçet’s disease: Experience of a single tertiary center
title Pediatric Behçet’s disease: Experience of a single tertiary center
title_full Pediatric Behçet’s disease: Experience of a single tertiary center
title_fullStr Pediatric Behçet’s disease: Experience of a single tertiary center
title_full_unstemmed Pediatric Behçet’s disease: Experience of a single tertiary center
title_short Pediatric Behçet’s disease: Experience of a single tertiary center
title_sort pediatric behçet’s disease: experience of a single tertiary center
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481698/
https://www.ncbi.nlm.nih.gov/pubmed/37680516
http://dx.doi.org/10.46497/ArchRheumatol.2023.9651
work_keys_str_mv AT acarıceyhun pediatricbehcetsdiseaseexperienceofasingletertiarycenter
AT isguderrana pediatricbehcetsdiseaseexperienceofasingletertiarycenter
AT torunruya pediatricbehcetsdiseaseexperienceofasingletertiarycenter
AT makaybalahan pediatricbehcetsdiseaseexperienceofasingletertiarycenter
AT unsalsevketerbil pediatricbehcetsdiseaseexperienceofasingletertiarycenter